Introduction {#Sec1}
============

Secondary occult hepatitis C infection (OCI) is defined as the presence of HCV-RNA in liver tissue or peripheral blood mononuclear cells (PBMCs) in anti-HCV-positive patients repeatedly negative for serum HCV-RNA who reached a sustained virological response (SVR) after antiviral therapy \[[@CR1]\]. Various types of lymphoid cells were shown to support HCV replication, being an important, long-term reservoir of the virus \[[@CR1]--[@CR3]\]. Viral infection of PBMCs in chronic hepatitis C (CHC) has a profound effect on immune cell function and carcinogenesis, leading to lymphocyte proliferative disorders, including mixed cryoglobulinemia and B cell non-Hodgkin lymphoma \[[@CR4], [@CR5]\]. Also persistence of residual HCV-RNA in PBMCs after therapy in SVR patients is linked with impaired immune responses \[[@CR6], [@CR7]\], as well as the risk of progressive liver disease and extrahepatic manifestations of HCV infection \[[@CR1], [@CR8]\].

The problem of OCI gained recently much attention with the introduction of interferon-free regiments for the treatment of CHC. Persistence of HCV-RNA in liver tissue after reaching SVR after direct-acting antivirals (DAAs) was shown in patients awaiting liver transplantation and in HCV-infected liver transplant recipients \[[@CR9], [@CR10]\]. The presence of HCV-RNA (−) strand, a signature of viral replication, was also documented in the latter group of patients \[[@CR10]\].

The general prevalence of OCI after therapy with DAA and the mechanisms leading to viral persistence remain unknown. Viral replication and production of HCV particles occurs in OCI at a very low level, which makes persisting HCV-RNA undetectable with conventional clinical tests of serum samples. *IFNL* genotype is a known predictor of spontaneous or treatment-induced HCV clearance \[[@CR11]\]. We aimed to investigate if basic immunological markers and *IFNL* genotype can be predictive of viral persistence after therapy with DAAs.

Patients and methods {#Sec2}
====================

Patients selection {#Sec3}
------------------

Forty-two consecutive CHC patients infected with HCV genotype 1b, treated with DAA for 12 weeks, who completed therapy between March 2015 and August 2016, were enrolled. All patients reached SVR and remained HCV-RNA negative in serum 24 weeks after the end of DAA therapy (SVR24) and during the follow-up. Before treatment all individuals were DAA naïve, 10 were treatment naïve, and 32 previously underwent ineffective IFN-based therapy. Baseline characteristics of patients are shown in Table S1. Patients received either ombitasvir, paritaprevir, ritonavir, dasabuvir, ribavirin (OBV/PTV/r + DSV ± RBV), sofosbuvir, ledipasvir, ribavirin (SOF/LDV + RBV), or sofosbuvir with ribavirin (SOF + RBV). Blood morphology and biochemical analyses in blood were routinely performed at the beginning of therapy, after 4, 8, 12, 24 and 48 weeks as well as at the follow-up (after 60--72 weeks). For each of the time points mean platelet volume (MPV) was recorded and ratio of neutrocyte (neutrophil) to lymphocyte counts (NLR) as well as platelet-to-lymphocyte count ratio (PLR) were calculated for every patient. Systemic immune-inflammation index (SII) was computed as platelet count × neutrocyte count/lymphocyte count. Normalization of alanine aminotransferase (ALT) at the follow-up was defined as ALT \< 40 IU/L. Detection of HCV-RNA was performed 12, 24, 48 weeks after therapy and at the follow-up with Cobas Amplicor (Roche) with detection limit 15 IU/mL.

The study protocol was approved by the Local Independent Bioethics Committee at the Medical University of Gdansk (NKEB 246/2011) in compliance with the Declaration of Helsinki. All participants provided written informed consent.

Detection of occult HCV infection {#Sec4}
---------------------------------

Whole-blood samples were collected at the follow-up 12--15 months after the end of therapy (EOT). PBMCs were isolated using density gradient centrifugation and incubated for 72 h in the presence of mitogens: phytohemagglutinin-M and concanavalin A. Cells were stored in − 80 °C prior to total RNA isolation. For total HCV-RNA detection RNA was reverse-transcribed with RevertAid Kit (Thermo Fisher, USA) using random hexamers as primers. For detection of HCV-RNA-negative strand RNA was transcribed with Tth polymerase (Promega, Germany) and forward Tth_F primer. Tth polymerase possesses intrinsic Mn-dependent reverse transcriptase activity and stability in high temperatures, which enables highly specific synthesis of cDNA and helps to overcome problems with RNA secondary structures. Final HCV-RNA detection of both total and negative strand of HCV-RNA was performed with real-time PCR using LightCycler 480 SYBR Green I Master and LightCycler 480 (Roche Applied Science, Germany) with 5′UTR_F and 5′UTR_R primers. Detection limit of the final amplification step was ≤ 1.5 IU/µg RNA (≤ 5 viral genomic equivalents/µg RNA) as determined using dilutions of pSGR-JFH1 plasmid \[[@CR12]\], containing whole HCV genome as a standard. During all the procedures both positive and negative controls were processed in parallel with patients' samples. Specificity of PCR products was confirmed by melting curve analysis and sequencing.

Primer sequences and details of the HCV-RNA detection procedures as well as exemplary results of HCV-RNA detection are shown in Supplementary Material (pp. 3--4; Fig. S1).

Genotyping {#Sec5}
----------

Genotyping of *IFNL3* rs12979860 and rs368234815 (*IFNL4* ss469415590) was performed as previously described \[[@CR11]\].

Statistical analysis {#Sec6}
--------------------

Statistical analysis was carried using data analysis software STATISTICA version 13.3 (StatSoft, Inc., USA). The software was also used for generation of graphs. All quantitative data are presented as median values with minimal to maximal range. The analysis was performed using two-sided Fisher's exact test for categorical data and two-sided Mann--Whitney *U* test with continuity correction for quantitative data. Logistic regression analysis was adjusted for age and sex. Allele distribution in European population was retrieved from 1000 Genomes Project Phase 3 database ([www.internationalgenome.org](http://www.internationalgenome.org)). Chi-square test was used for comparison with the results. Two-sided sign test for matched pairs was applied to compare the same parameters between different time points. *P* values less than 0.05 were considered statistically significant.

Results {#Sec7}
=======

Selected characteristics of individual patients during and after DAA therapy are shown in Table S2. All 42 subjects were HCV-RNA negative in serum 24 weeks and remained negative 12--15 months after EOT. Thirty-one patients (74%) were positive for HCV-RNA in PBMCs, and in 29 (69%) of them we confirmed the presence of HCV-RNA (−) strand. Normalization of ALT at the follow-up was noted in 34 individuals (81%). Neither ALT level nor ALT normalization after therapy correlated with the presence of HCV-RNA (Tables [1](#Tab1){ref-type="table"}, S2; Fig. S2). Treatment with OBV/PTV/r + DSV ± RBV was most effective in eradication of replicative viral RNA strand (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of groups of patients with or without HCV-RNA (−) strand in PBMCsCharacteristicsHCV-RNA (−) strand in PBMC*P* value^a^Present (*n* = 29)Absent (*n* = 13)Age55 (29--66)59 (39--70)0.136Sex (female)14 (48%)7 (54%)1.000Liver cirrhosis^b^20 (69%)10 (77%)0.722HCC^b^3 (10%)00.540Cryoglobulinemia^b^6 (21%)3 (23%)1.000Treatment naïve6 (21%)4 (31%)0.697Duration of CHC (years)^c^11 (0.5--18)12 (2--19)0.851HCV-RNA (kIU/mL)^b^817 (3.1--17,650)1027.5 (13.2--37,900)0.988DAA treatment OBV/PTV/r + DSV ± RBV12 (41%)11 (85%)**0.017** SOF/LDV + RBV15 (52%)2 (15%)**0.041** SOF + RBV2 (7%)00.471IFNλ3 rs12979860 genotype CC4 (14%)4 (31%)0.226 TT8 (28%)1 (8%)0.231 CT17 (59%)8 (62%)0.567Adverse events^d^7 (24%)3 (23%)1.000Normalization of ALT at follow-up22 (76%)12 (92%)0.398Δ neutrocyte count (EOT--baseline) \[× 10^9^ cells/L\]0.03 (− 1.22--4.64)0.69 (− 0.57--3.32)**0.028**Δ lymphocyte count (EOT--baseline) \[× 10^9^ cells/L\]− 0.19 (− 1.42--1.05)− 0.32 (− 0.81--0.23)0.374Significant *P* values \< 0.05 are given in bold*ALT* alanine aminotransferase; *CHC* chronic hepatitis C; *EOT* end of treatment; *OBV/PTV/r+DSV±RBV* ombitasvir, paritaprevir, ritonavir, dasabuvir, ribavirin; *SOF*/*LDV* + *RBV* sofosbuvir, ledipasvir, ribavirin; *SOF* + *RBV* sofosbuvir, ribavirin. For quantitative data median values with minimal maximal range are given^a^For differences between groups with and without HCV-RNA (−) in PBMCs, two-sided Fisher's exact test for categorical data, two-sided Mann--Whitney *U* test with continuity correction for quantitative data^b^Before DAA therapy^c^From the diagnosis of CHC to the start of DAA treatment^d^Adverse events during therapy and follow-up

In case of 10 patients adverse events occurred during DAA therapy and follow-up (Table S2), including portal vein thrombosis with liver failure, ascites, severe bacterial infections, vasculitis, nephropathy, monoclonal gammopathy, lymphomas and rapidly elevating ALT after treatment (Table S2). In three cases of hepatocellular carcinoma (HCC) diagnosed and treated with radiofrequency ablation before therapy no recurrence was observed during follow-up. Occurrence of adverse events did not correlate with the presence of HCV-RNA in PBMCs (Table [1](#Tab1){ref-type="table"}, Table S3), but it associated with lower lymphocyte counts during and after therapy (Fig. S3).

Polymorphisms rs368234815 ΔG/T and rs12979860 T/C were in a complete linkage disequilibrium (*r*2 = 1), so further we will refer only to rs12979860. Allele frequencies for rs12979860 (*f*~C~ = 0.488; *f*~T~ = 0.512) differed significantly from their distribution in European population (*f*~C~ = 0.691; *f*~T~ = 0.309), with unfavorable, minor T allele being more frequent than in population (Chi^2^ = 16.197; *P* \< 0.0001). There was no correlation between *IFNL3* genotype and the presence of HCV-RNA in PBMCs (Table [1](#Tab1){ref-type="table"}; Table S3). Favorable homozygote rs12979860 CC had lower neutrocyte levels at the beginning of therapy (2.2 vs. 3.2 × 10^9^ cells/L; *P* = 0.024) and after 24 weeks (2.3 vs. 3.3 × 10^9^ cells/L; *P* = 0.037) (Fig. S4).

Test for matched pairs revealed that for all patients significant fall of lymphocyte number occurred during therapy \[1.75 × 10^9^ (0.61--4.5) vs. 1.32 × 10^9^ (0.42--5.36) at EOT; *P* = 0.009)\], and neutrophils remained at the same level (*P* = 0.090) (Fig. S5A--B). During 12 weeks of therapy NLR, SII and PLR values rose significantly for all individuals (*P* \< 0.0001 for all markers), while MPV decreased (*P* = 0.001) (Fig. S5C--F). Additionally, SII and PLR remained significantly higher from baseline at the follow-up (*P* = 0.02 and 0.044, respectively) (Fig. S5D--E).

There were no significant differences in neutrocyte and lymphocyte counts between groups of patients with or without viral RNA in PBMCs (Fig. [1](#Fig1){ref-type="fig"}a, b). However, a smaller increase in neutrocyte count between EOT and baseline was observed in patients with HCV-RNA (−) (Table [1](#Tab1){ref-type="table"}). Higher NLR value during and shortly after therapy associated with clearance of replicative HCV-RNA strand (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}c). Among patients without HCV-RNA (−) NLR was significantly higher from baseline at 4, 8, 12 weeks after the start of therapy (*P* values from sign test 0.027, 0.006 and 0.006, respectively), while in the group with replicative strand NLR was significantly raised from baseline only after 12 weeks (*P* = 0.001) (Fig. [1](#Fig1){ref-type="fig"}c). Also lower SII linked with detected HCV-RNA (−) in PBMC but only at 4 and 24 weeks after the start of therapy (Table S4; Fig. S6A). Association of NLR and SII with the presence of total HCV-RNA in PBMCs was much weaker (Table S2, Table S4). There were no significant differences in PLR or MPV between groups of patients (Table S4; Fig. S6B--C). Fig. 1Changes in neutrocyte and lymphocyte counts and NLR values for groups of patients with or without HCV-RNA (−) strand. Neutrocyte (**a**) and lymphocyte (**b**) counts as well as NLR values (**c**) were recorded during 12 weeks of DAA treatment and up to 60--72 weeks (follow-up) after the start of therapy. Points show median values; whiskers represent percentiles (25th to 75th). Filled circles, patients with HCV-RNA (−) strand in PBMCs; empty squares, patients without HCV-RNA (−) strand detected in PBMCs. NLR, neutrocyte-to-lymphocyte ratio; \*, significant (*P* \< 0.05) differences between groups of patients in a given time point calculated with two-sided Mann--Whitney *U* testTable 2NLR values in groups of patients with or without HCV-RNA (−) strand in PBMCsCharacteristicsHCV-RNA (−) strand in PBMC*P* value^a^OR (CI 95%)^b^*P* value^b^Present (*n* = 29)Absent (*n* = 13)0-week NLR1.5 (0.5--7.5)1.6 (0.8--6.3)0.3050.80 (0.51--1.27)0.3304-week NLR1.6 (0.6--5.4)2.3 (1.0--59.0)**0.012**0.68 (0.36--1.30)0.2308-week NLR1.6 (0.8--6.2)2.2 (1.4--8.4)**0.011**0.69 (0.41--1.17)0.15612-week NLR (EOT)1.9 (0.6--3.7)3.0 (1.3--9.3)**0.017**0.65 (0.40--1.06)0.07724-week NLR1.4 (0.5--3.7)2.2 (1.5--4.6)**0.002**0.23 (0.10--0.86)**0.019**48-week NLR (SVR24)1.6 (0.5--5.7)2.2 (1.4--4.6)**0.021**0.65 (0.34--1.23)0.17260--72-week NLR (follow-up)1.5 (0.7--5.7)1.9 (0.8--4.6)0.1850.87 (0.47--1.62)0.647Median NLR values with minimal to maximal range are givenSignificant *P* values \< 0.05 are given in bold*EOT* end of treatment; *NLR* neutrocyte-to-lymphocyte ratio; *OR* odds ratio; *CI* confidence intervals^a^For difference between groups with and without HCV-RNA (−), two-sided Mann--Whitney *U* test with continuity correction^b^Logistic regression analysis adjusted for age and sex

Discussion {#Sec8}
==========

This brief report shows high occurrence of occult HCV infection in patients who reached SVR24 after DAAs. In the majority of these subjects we also found a replicative HCV-RNA (−) strand. These results are consistent with observations of Elmasry et al. that while in the liver of CHC patients a 1--3 logs difference in the number of copies is seen in favor of HCV-RNA (+) strand, in OCI the amounts of HCV-RNA (+) and (−) strand are similar \[[@CR10]\].

Normalization of ALT was not a predictor of OCI or the presence of HCV-RNA (−). This is in accordance with recent report in which elevated liver enzymes after DAA therapy did not predict persistence of viral RNA \[[@CR10]\]. Additionally, OCI has been frequently detected in patients after successful IFN-based therapy having normal levels of liver enzymes \[[@CR13], [@CR14]\].

It is now established that genetic variations within *IFNL3*-*IFNL4* gene region impact interferon-stimulated gene expression (ISGs) both in the liver and in PBMCs of CHC patients and are predictors of spontaneous and treatment-induced HCV clearance in both DAA- and IFN-based therapy \[[@CR15]--[@CR17]\]. However, their impact on development of OCI is still unclear. Elmasry et al. \[[@CR10]\] examined 9 liver transplant recipients who did not reach normalization of liver enzymes after DAA therapy. They found OCI in all homozygotes in unfavorable rs12979860 T allele (*n* = 5), while carriers of C/T and CC alleles did not have HCV-RNA in liver tissue or PBMCs \[[@CR10]\]. In another study prevalence of the rs12979860 CC genotype was significantly higher in patients with seronegative OCI (no anti-HCV Abs) than in CHC group. Additionally, among patients with this type of occult infection the presence of rs12979860 CC genotype associated with lower HCV-RNA load in liver tissue \[[@CR18]\]. Polymorphisms in the *IFNL3*-*IFNL4* region also link with the presence of HCV-RNA in PBMCs both during chronic HCV infection and in patients who reached SVR after IFN treatment \[[@CR19], [@CR20]\]. We found no significant correlation between *IFNL* genotype and the occurrence of HCV-RNA in PBMCs. This may be due to a small group of patients which is not representative of a whole population, as the unfavorable rs12979860 T allele is significantly more prevalent in the tested group. It was shown that at the beginning of DAA therapy rs12979860 CC carriers exhibit decreased expression of ISGs in peripheral blood and liver \[[@CR17]\]. As ISGs represent a diverse group of gene products which can also act as inflammatory cytokines this observation corresponds to lower neutrocyte levels at baseline observed in our study for rs12979860 C homozygotes.

We aimed to evaluate if markers of systemic inflammation, such as NLR, SII, PLR and MPV, which are useful prognostic factors in many chronic diseases, can predict development of OCI after DAAs. It was reported that increased PLR in CHC patients during therapy predicts a good virological response \[[@CR21]\]. MPV indicates inflammation and liver damage in CHC patients \[[@CR22]\], while SII is a prognostic factor in patients with HCC \[[@CR23]\].

Therapy with DAAs is known to evoke dynamic changes in cytokine profile and in the balance between neutrophil and lymphocyte counts, as well as to induce a general inflammatory state \[[@CR23]--[@CR25]\]. In DAA-treated patients a significantly greater increase in neutrophil counts and decrease in lymphocyte numbers between EOT and baseline associated with later development of HCC after therapy \[[@CR25]\]. Viral clearance and SVR induced by DAA therapy is accompanied with downregulation of signaling with type II and type III IFNs, but also with elevation of IFN I cellular pathways, which can promote elimination of the virus \[[@CR26]\]. In patients achieving SVR after DAAs ISGs expression in liver and blood at EOT is significantly increased in comparison with baseline \[[@CR27]\].

We found that a significant and transient rise in NLR, a marker of systemic inflammation, during and shortly after DAA therapy can predict the clearance of replicating HCV from PBMCs. Additionally, patients without HCV-RNA (−) strand had a significantly greater increase in neutrocyte counts between EOT and baseline. We hypothesize that differences in patient's immune responsiveness at baseline and in the ability to induce general inflammatory response after viral suppression by DAAs determine subsequent HCV persistence/clearance. Although this systemic inflammation could be beneficial for complete eradication of HCV, it might also favor carcinogenesis \[[@CR23], [@CR25]\].

Our study is limited by a small sample size and restricted to patients infected with HCV genotype 1. Therefore, further research on larger cohorts is needed to find if transient rise in NLR could be used as a predictor of viral clearance. Also long-term follow-up studies of patients with residual HCV-RNA should be performed to examine the natural course of secondary occult infection after DAAs and its clinical significance.
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